Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid

Stephen D. Weigand, Prashanthi D Vemuri, Heather J. Wiste, Matthew L. Senjem, Vernon S. Pankratz, Paul S. Aisen, Michael W. Weiner, Ronald Carl Petersen, Leslie M. Shaw, John Q. Trojanowski, David S Knopman, Clifford R Jr. Jack

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background: Positron-emission tomography (PET) imaging of amyloid with Pittsburgh Compound B (PIB) and Aβ42 levels in the cerebrospinal fluid (CSF Aβ42) demonstrate a highly significant inverse correlation. Both these techniques are presumed to measure brain Aβ amyloid load. The objectives of this study were to develop a method to transform CSF Aβ42 measures into calculated PIB measures (PIBcalc) of Aβ amyloid load, and to partially validate the method in an independent sample of subjects. Methods: In all, 41 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent PIB PET imaging and lumbar puncture (LP) at the same time. This sample, referred to as the "training" sample (nine cognitively normal subjects, 22 subjects with mild cognitive impairment, and 10 subjects with Alzheimer's disease), was used to develop a regression model by which CSF Aβ42 (with apolipoprotein E ε4 carrier status as a covariate) was transformed into units of PIB PET (PIBcalc). An independent "supporting" sample of 362 ADNI subjects (105 cognitively normal subjects, 164 subjects with mild cognitive impairment, and 93 subjects with Alzheimer's disease) who underwent LP but not PIB PET imaging had their CSF Aβ42 values converted to PIBcalc. These values were compared with the overall PIB PET distribution found in the ADNI subjects (n = 102). Results: A linear regression model demonstrates good prediction of actual PIB PET from CSF Aβ42 measures obtained in the training sample (R2 = 0.77, P < .001). PIBcalc data (derived from CSF Aβ42) in the supporting sample of 362 ADNI subjects who underwent LP but not PIB PET imaging demonstrate group-wise distributions that are highly consistent with the larger ADNI PIB PET distribution and with published PIB PET imaging studies. Conclusion: Although the precise parameters of this model are specific for the ADNI sample, we conclude that CSF Aβ42 can be transformed into PIBcalc measures of Aβ amyloid load. Brain Aβ amyloid load can be ascertained at baseline in therapeutic or observational studies by either CSF or amyloid PET imaging and the data can be pooled using well-established multiple imputation techniques that account for the uncertainty in a CSF-based PIBcalc value.

Original languageEnglish (US)
Pages (from-to)133-141
Number of pages9
JournalAlzheimer's and Dementia
Volume7
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Amyloid
Positron-Emission Tomography
Cerebrospinal Fluid
Alzheimer Disease
Neuroimaging
Brain
Spinal Puncture
Linear Models
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
Apolipoprotein E4
Uncertainty
Observational Studies

Keywords

  • Aβ amyloid
  • Alzheimer's disease
  • Alzheimer's disease biomarkers
  • Amyloid imaging
  • Cerebrospinal fluid
  • Pittsburgh compound B

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid. / Weigand, Stephen D.; Vemuri, Prashanthi D; Wiste, Heather J.; Senjem, Matthew L.; Pankratz, Vernon S.; Aisen, Paul S.; Weiner, Michael W.; Petersen, Ronald Carl; Shaw, Leslie M.; Trojanowski, John Q.; Knopman, David S; Jack, Clifford R Jr.

In: Alzheimer's and Dementia, Vol. 7, No. 2, 03.2011, p. 133-141.

Research output: Contribution to journalArticle

Weigand, Stephen D. ; Vemuri, Prashanthi D ; Wiste, Heather J. ; Senjem, Matthew L. ; Pankratz, Vernon S. ; Aisen, Paul S. ; Weiner, Michael W. ; Petersen, Ronald Carl ; Shaw, Leslie M. ; Trojanowski, John Q. ; Knopman, David S ; Jack, Clifford R Jr. / Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid. In: Alzheimer's and Dementia. 2011 ; Vol. 7, No. 2. pp. 133-141.
@article{3bb15274b1eb4d1ca0434f247bfdec92,
title = "Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid",
abstract = "Background: Positron-emission tomography (PET) imaging of amyloid with Pittsburgh Compound B (PIB) and Aβ42 levels in the cerebrospinal fluid (CSF Aβ42) demonstrate a highly significant inverse correlation. Both these techniques are presumed to measure brain Aβ amyloid load. The objectives of this study were to develop a method to transform CSF Aβ42 measures into calculated PIB measures (PIBcalc) of Aβ amyloid load, and to partially validate the method in an independent sample of subjects. Methods: In all, 41 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent PIB PET imaging and lumbar puncture (LP) at the same time. This sample, referred to as the {"}training{"} sample (nine cognitively normal subjects, 22 subjects with mild cognitive impairment, and 10 subjects with Alzheimer's disease), was used to develop a regression model by which CSF Aβ42 (with apolipoprotein E ε4 carrier status as a covariate) was transformed into units of PIB PET (PIBcalc). An independent {"}supporting{"} sample of 362 ADNI subjects (105 cognitively normal subjects, 164 subjects with mild cognitive impairment, and 93 subjects with Alzheimer's disease) who underwent LP but not PIB PET imaging had their CSF Aβ42 values converted to PIBcalc. These values were compared with the overall PIB PET distribution found in the ADNI subjects (n = 102). Results: A linear regression model demonstrates good prediction of actual PIB PET from CSF Aβ42 measures obtained in the training sample (R2 = 0.77, P < .001). PIBcalc data (derived from CSF Aβ42) in the supporting sample of 362 ADNI subjects who underwent LP but not PIB PET imaging demonstrate group-wise distributions that are highly consistent with the larger ADNI PIB PET distribution and with published PIB PET imaging studies. Conclusion: Although the precise parameters of this model are specific for the ADNI sample, we conclude that CSF Aβ42 can be transformed into PIBcalc measures of Aβ amyloid load. Brain Aβ amyloid load can be ascertained at baseline in therapeutic or observational studies by either CSF or amyloid PET imaging and the data can be pooled using well-established multiple imputation techniques that account for the uncertainty in a CSF-based PIBcalc value.",
keywords = "Aβ amyloid, Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid imaging, Cerebrospinal fluid, Pittsburgh compound B",
author = "Weigand, {Stephen D.} and Vemuri, {Prashanthi D} and Wiste, {Heather J.} and Senjem, {Matthew L.} and Pankratz, {Vernon S.} and Aisen, {Paul S.} and Weiner, {Michael W.} and Petersen, {Ronald Carl} and Shaw, {Leslie M.} and Trojanowski, {John Q.} and Knopman, {David S} and Jack, {Clifford R Jr.}",
year = "2011",
month = "3",
doi = "10.1016/j.jalz.2010.08.230",
language = "English (US)",
volume = "7",
pages = "133--141",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid

AU - Weigand, Stephen D.

AU - Vemuri, Prashanthi D

AU - Wiste, Heather J.

AU - Senjem, Matthew L.

AU - Pankratz, Vernon S.

AU - Aisen, Paul S.

AU - Weiner, Michael W.

AU - Petersen, Ronald Carl

AU - Shaw, Leslie M.

AU - Trojanowski, John Q.

AU - Knopman, David S

AU - Jack, Clifford R Jr.

PY - 2011/3

Y1 - 2011/3

N2 - Background: Positron-emission tomography (PET) imaging of amyloid with Pittsburgh Compound B (PIB) and Aβ42 levels in the cerebrospinal fluid (CSF Aβ42) demonstrate a highly significant inverse correlation. Both these techniques are presumed to measure brain Aβ amyloid load. The objectives of this study were to develop a method to transform CSF Aβ42 measures into calculated PIB measures (PIBcalc) of Aβ amyloid load, and to partially validate the method in an independent sample of subjects. Methods: In all, 41 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent PIB PET imaging and lumbar puncture (LP) at the same time. This sample, referred to as the "training" sample (nine cognitively normal subjects, 22 subjects with mild cognitive impairment, and 10 subjects with Alzheimer's disease), was used to develop a regression model by which CSF Aβ42 (with apolipoprotein E ε4 carrier status as a covariate) was transformed into units of PIB PET (PIBcalc). An independent "supporting" sample of 362 ADNI subjects (105 cognitively normal subjects, 164 subjects with mild cognitive impairment, and 93 subjects with Alzheimer's disease) who underwent LP but not PIB PET imaging had their CSF Aβ42 values converted to PIBcalc. These values were compared with the overall PIB PET distribution found in the ADNI subjects (n = 102). Results: A linear regression model demonstrates good prediction of actual PIB PET from CSF Aβ42 measures obtained in the training sample (R2 = 0.77, P < .001). PIBcalc data (derived from CSF Aβ42) in the supporting sample of 362 ADNI subjects who underwent LP but not PIB PET imaging demonstrate group-wise distributions that are highly consistent with the larger ADNI PIB PET distribution and with published PIB PET imaging studies. Conclusion: Although the precise parameters of this model are specific for the ADNI sample, we conclude that CSF Aβ42 can be transformed into PIBcalc measures of Aβ amyloid load. Brain Aβ amyloid load can be ascertained at baseline in therapeutic or observational studies by either CSF or amyloid PET imaging and the data can be pooled using well-established multiple imputation techniques that account for the uncertainty in a CSF-based PIBcalc value.

AB - Background: Positron-emission tomography (PET) imaging of amyloid with Pittsburgh Compound B (PIB) and Aβ42 levels in the cerebrospinal fluid (CSF Aβ42) demonstrate a highly significant inverse correlation. Both these techniques are presumed to measure brain Aβ amyloid load. The objectives of this study were to develop a method to transform CSF Aβ42 measures into calculated PIB measures (PIBcalc) of Aβ amyloid load, and to partially validate the method in an independent sample of subjects. Methods: In all, 41 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent PIB PET imaging and lumbar puncture (LP) at the same time. This sample, referred to as the "training" sample (nine cognitively normal subjects, 22 subjects with mild cognitive impairment, and 10 subjects with Alzheimer's disease), was used to develop a regression model by which CSF Aβ42 (with apolipoprotein E ε4 carrier status as a covariate) was transformed into units of PIB PET (PIBcalc). An independent "supporting" sample of 362 ADNI subjects (105 cognitively normal subjects, 164 subjects with mild cognitive impairment, and 93 subjects with Alzheimer's disease) who underwent LP but not PIB PET imaging had their CSF Aβ42 values converted to PIBcalc. These values were compared with the overall PIB PET distribution found in the ADNI subjects (n = 102). Results: A linear regression model demonstrates good prediction of actual PIB PET from CSF Aβ42 measures obtained in the training sample (R2 = 0.77, P < .001). PIBcalc data (derived from CSF Aβ42) in the supporting sample of 362 ADNI subjects who underwent LP but not PIB PET imaging demonstrate group-wise distributions that are highly consistent with the larger ADNI PIB PET distribution and with published PIB PET imaging studies. Conclusion: Although the precise parameters of this model are specific for the ADNI sample, we conclude that CSF Aβ42 can be transformed into PIBcalc measures of Aβ amyloid load. Brain Aβ amyloid load can be ascertained at baseline in therapeutic or observational studies by either CSF or amyloid PET imaging and the data can be pooled using well-established multiple imputation techniques that account for the uncertainty in a CSF-based PIBcalc value.

KW - Aβ amyloid

KW - Alzheimer's disease

KW - Alzheimer's disease biomarkers

KW - Amyloid imaging

KW - Cerebrospinal fluid

KW - Pittsburgh compound B

UR - http://www.scopus.com/inward/record.url?scp=79952740168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952740168&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2010.08.230

DO - 10.1016/j.jalz.2010.08.230

M3 - Article

C2 - 21282074

AN - SCOPUS:79952740168

VL - 7

SP - 133

EP - 141

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 2

ER -